Draft:Recce Pharmaceuticals Ltd

Recce Pharmaceuticals Adds Biotech Veteran Alan W. Dunton M.D. to its Board of Directors

Retrieved on: 
Tuesday, July 14, 2020
Recce, Antibiotic, South African Special Forces, Severe acute respiratory syndrome-related coronavirus, Pharmaceutical industry, Military units and formations, Articles, Military, Draft:Recce Pharmaceuticals Ltd

On behalf of all the team at Recce, we welcome Dr. Dunton to our Board of Directors, stated Dr. John Prendergast, Recce Pharmaceuticals Non-Executive Chairman.

Key Points: 
  • On behalf of all the team at Recce, we welcome Dr. Dunton to our Board of Directors, stated Dr. John Prendergast, Recce Pharmaceuticals Non-Executive Chairman.
  • Alan joins us at a critical time as we move into the second half of 2020, where we anticipate a number of human clinical trials evaluating our broad-spectrum novel antibiotic, RECCE 327.
  • In addition, we will continue to investigate the efficacy of our synthetic compounds against SARS-CoV-2 among other key clinical development milestones.
  • Recces anti-infective pipeline seeks to exploit the unique capabilities of RECCE technologies targeting synergistic, unmet medical needs.

Recce Pharmaceuticals Announces RECCE® Compounds Selected by CSIRO/Doherty Institute in Priority 1 Candidate Group for SARS-CoV-2 Antiviral Screening Program

Retrieved on: 
Wednesday, July 8, 2020
Medical specialties, Medicine, Health, Biocides, Antibiotic, Antiviral drug, Infection, Antiseptic, Sepsis, Draft:Recce Pharmaceuticals Ltd, Medical specialties, Medicine, Health, Biocides, Antibiotic, Antiviral drug, Infection, Antiseptic, Sepsis, Draft:Recce Pharmaceuticals Ltd

RECCE 327 is a broad-spectrum synthetic antibiotic formulated using synthetic polymer technology to treat blood infections and sepsis.

Key Points: 
  • RECCE 327 is a broad-spectrum synthetic antibiotic formulated using synthetic polymer technology to treat blood infections and sepsis.
  • RECCE 529 is a new synthetic polymer formulation, built upon the Companys anti-infective expertise.
  • According to the Program Selection Guidelines, Priority 1 status is defined as highest or strong likelihood of antiviral or antiseptic efficacy Compounds in this grouping will be eligible for stage 1 laboratory screening trials.
  • The Program is part of the Australian Governments efforts to identify promising anti-viral candidates and fast-track research into potential treatments for COVID-19.

Recce Pharmaceuticals Announces Resignation of Director & Chief Research Officer Dr. Graham Melrose

Retrieved on: 
Monday, July 6, 2020
Health, Antibiotic, Recce, Pharmaceutical industry, Articles, Draft:Recce Pharmaceuticals Ltd

SYDNEY, Australia, July 06, 2020 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE) (Company), the Company developing new classes of broad-spectrum synthetic antibiotics, today announced the completion of Dr. Graham Melroses executive service agreement as Chief Research Officer and his resignation as Executive Director from the Board.

Key Points: 
  • SYDNEY, Australia, July 06, 2020 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE) (Company), the Company developing new classes of broad-spectrum synthetic antibiotics, today announced the completion of Dr. Graham Melroses executive service agreement as Chief Research Officer and his resignation as Executive Director from the Board.
  • The Company is now well setup to pursue its objectives, with expanding indications across a range of significant and unmet infectious diseases.
  • A pioneer in synthetic antibiotic development, Dr. Melrose founded Recce Pharmaceuticals Ltd in 2008, later co-inventing RECCE antibiotics with Executive Director Michele Dilizia.
  • Recces anti-infective pipeline seeks to exploit the unique capabilities of RECCE technologies targeting synergistic, unmet medical needs.

Recce Pharmaceuticals Announces Positive Data on RECCE® 327 Against Neisseria gonorrhoeae in STD Animal Model

Retrieved on: 
Monday, May 4, 2020
Carbapenem antibiotics, Drugs, Organic compounds, Pyrrolidines, Chemistry, Carbapenem, Antibiotic, Recce, Meropenem, Draft:Recce Pharmaceuticals Ltd

In this study Meropenem, a broad spectrum carbapenem antibiotic, was used at its optimum dose as the recognized efficacy model.

Key Points: 
  • In this study Meropenem, a broad spectrum carbapenem antibiotic, was used at its optimum dose as the recognized efficacy model.
  • The FDA has awarded RECCE 327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval.
  • Recce wholly owns its automated manufacturing, ready to support first-in-human clinical trials.
  • Recces anti-infective pipeline seeks to exploit the unique capabilities of RECCE technologies targeting synergistic, unmet medical needs.

Recce Pharmaceuticals Announces First-Quarter 2020 Financial Results and Provides Operational Highlights

Retrieved on: 
Thursday, April 30, 2020
Antibiotic, Pharmaceutical industry, Draft:Recce Pharmaceuticals Ltd

SYDNEY, Australia, April 29, 2020 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE) (Company), the company developing a new class of broad-spectrum synthetic antibiotics, today reported its March 2020 quarter results and operational highlights.

Key Points: 
  • SYDNEY, Australia, April 29, 2020 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE) (Company), the company developing a new class of broad-spectrum synthetic antibiotics, today reported its March 2020 quarter results and operational highlights.
  • Research and development of RECCE 327 was the main source of expenditure at AUD $817,255 during the period.
  • During the month of February, the Company announced successful in-vivo toxicity (safety) studies in small and large animal species; further reinforcing indications of RECCE 327s wide therapeutic window.
  • This indicates potential of RECCE antibiotics to tackle infections at their earlier infection stage as part of investigating a whole system therapeutic approach.

Recce Signs Phase I Clinical Trial Agreement to Initiate Study of Synthetic Antibiotic RECCE® 327 in Healthy Subjects

Retrieved on: 
Wednesday, April 8, 2020
Medical specialties, Medicine, Infectious diseases, Bacterial diseases, Pathogenic bacteria, Healthcare-associated infections, Intensive care medicine, Staphylococcus aureus, Antibiotic, Sepsis, Bacteremia, Draft:Recce Pharmaceuticals Ltd

The Phase I clinical study of RECCE 327 will be conducted at a specialized clinical trial facility in Sydney, Australia, independent of the hospital system.

Key Points: 
  • The Phase I clinical study of RECCE 327 will be conducted at a specialized clinical trial facility in Sydney, Australia, independent of the hospital system.
  • This initiative seeks to ensure continuity of the independent study and not add to infectious disease pressures for beds around the country.
  • Recce Chairman Dr. John Prendergast said, The formalization of the clinical trial agreement is a major milestone towards advancing RECCE 327 through the clinic.
  • RECCE 327 is a broad-spectrum synthetic antibiotic formulated using synthetic polymer technology to treat blood infections and sepsis derived from Escherichia coli and Staphylococcus aureus bacteria.

The Antimicrobial Crisis: New Antibiotics Could Avert 230,000 Deaths Per Year

Retrieved on: 
Thursday, January 30, 2020
Health, Medicine, Articles, Evolutionary biology, Pharmaceuticals policy, Veterinary medicine, Antimicrobial resistance, Multiple drug resistance, Antibiotic, Drug resistance, Antimicrobial, Draft:Recce Pharmaceuticals Ltd

Recent clinical studies presented at the International Symposium organized by the Fondazione Internazionale Menarini held in Genova, where leading experts came together for an update on antimicrobial resistance, support these findings.

Key Points: 
  • Recent clinical studies presented at the International Symposium organized by the Fondazione Internazionale Menarini held in Genova, where leading experts came together for an update on antimicrobial resistance, support these findings.
  • Every year infections related to antibiotic-resistant superbugs kill 700,000 people worldwide, 33,000 of which in Europe.
  • The decline in private investments and a lack of innovation in the development path of new antibiotics will undermine the efforts made to tackle drug-resistant infections.
  • "A number of these new molecules have already been approved by the Food Drug Administration and the European Medicines Agency.

The Antimicrobial Crisis: New Antibiotics Could Avert 230,000 Deaths Per Year

Retrieved on: 
Thursday, January 30, 2020
Health, Medicine, Articles, Evolutionary biology, Pharmaceuticals policy, Veterinary medicine, Antimicrobial resistance, Multiple drug resistance, Antibiotic, Drug resistance, Antimicrobial, Draft:Recce Pharmaceuticals Ltd

Recent clinical studies presented at the International Symposium organized by the Fondazione Internazionale Menarini held in Genova, where leading experts came together for an update on antimicrobial resistance, support these findings.

Key Points: 
  • Recent clinical studies presented at the International Symposium organized by the Fondazione Internazionale Menarini held in Genova, where leading experts came together for an update on antimicrobial resistance, support these findings.
  • Every year infections related to antibiotic-resistant superbugs kill 700,000 people worldwide, 33,000 of which in Europe.
  • The decline in private investments and a lack of innovation in the development path of new antibiotics will undermine the efforts made to tackle drug-resistant infections.
  • "A number of these new molecules have already been approved by the Food Drug Administration and the European Medicines Agency.

Global Antibiotic Resistance Markets, & 2020-2024: Key Large Market Opportunities / Therapeutic Technology / Recent Developments

Retrieved on: 
Thursday, October 31, 2019
Articles, Health, Evolutionary biology, Pharmaceuticals policy, Veterinary medicine, Life sciences, Antimicrobial resistance, Antibiotic, Biotechnology, Antimicrobial, Draft:Recce Pharmaceuticals Ltd

Antimicrobial Resistance is creating new kinds of infections and superbugs that are resistant to current antibiotic medicines.

Key Points: 
  • Antimicrobial Resistance is creating new kinds of infections and superbugs that are resistant to current antibiotic medicines.
  • New technologies (and new drugs) are under development to capture this growing market.
  • We have identified the 6 Key Large Opportunities in this space and developed market forecasts.
  • This is a market with a lot of players, there are over 100 biotechnology companies profiled in the report.